Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma
Martin Dreyling, Franck Morschhauser, Dominique Bron et al.
Key Points:
- Examine activity and safety of BAY 80-6946 in patients with relapsed or refractory indolent or aggressive lymphoma.
- Patients with ≥2 prior lines of treatment received BAY 80-6946 - dose of 0.8 mg/kg, days 1, 8 and 15 of 28-day cycle and continued until progression
- In CLL patients ORR - 67% and complete RR - 0%.
Implications:
- BAY 80-6946, novel PI3K inhibitor as single agent has promising activity observed in CLL, FL, MCL and PTCL with acceptable toxicity profile.
View the original abstract on the ASH website.
